Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 893

Sort by

Sort Order Select

Journal Articles

The role of AGK in thrombocytopoiesis and possible therapeutic strategies

Haojie Jiang, Zhuo Yu, Nan Ding, Mina Yang, Lin Zhang, Xuemei Fan, Yuan Zhou, Qiang Zou, Jian Hou, Junke Zheng, Lei Zhang, Yanyan Xu, Junling Liu

Blood (2020) 136 (1): 119–129.

https://doi.org/10.1182/blood.2019003851

Published: 2020

Includes: Supplemental data

Journal Articles

Eltrombopag for Immune Thrombocytopenia Adult Patients in the Real-Life Practice in France. Interim Results of the Elextra Study

Guillaume Moulis, MD PhD, Manuela Rueter, MSc, Margaux Lafaurie, PharmD, Maryse Lapeyre-Mestre, MD PhD, Carmen investigators Group

Blood (2019) 134 (Supplement_1): 2372.

https://doi.org/10.1182/blood-2019-126000

Published: 2019

Journal Articles

Megakaryocyte Ablation Ameliorates Bone Marrow Fibrosis By Reducing Myofibroblast Differentiation in a Mouse Model of Primary Myelofibrosis

Yutein Chung, PhD, Huiyan Jin, PhD, Claire Trasorras, Francina Gonzalez, Sang Hee Min, MD PhD

Blood (2019) 134 (Supplement_1): 2493.

https://doi.org/10.1182/blood-2019-132186

Published: 2019

Journal Articles

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Ivy Altomare, MD, Anna Nguyen, PharmD, MPH, Shreekant Parasuraman, BPharm, PhD, Dilan Paranagama, PhD, Jonathan K. Kish, PhD MPH, Kevin Lord, PhD MHS, Philomena Colucci, DO, MS

Blood (2019) 134 (Supplement_1): 4192.

https://doi.org/10.1182/blood-2019-127442

Published: 2019

Journal Articles

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Juan Shen, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 4165.

https://doi.org/10.1182/blood-2019-130069

Published: 2019

Journal Articles

High Platelet Counts, Thrombosis, Bleeding Signs, and Acquired Von Willebrand Syndrome at Diagnosis of Pediatric Chronic Myeloid Leukemia

Meinolf Suttorp, MD PhD, Ralf Knoefler, MD PhD, Hélène Deutsch, MD, Franziska Paul, cand. MD, Oliver Tiebel, MD, Markus Metzler, MD PhD, Frederic Millot

Blood (2019) 134 (Supplement_1): 4152.

https://doi.org/10.1182/blood-2019-123343

Published: 2019

Journal Articles

Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms

Emma Difilippo, BS, Giacomo Coltro, MD, Ryan M. Carr, MD PhD, Abhishek A Mangaonkar, MBBS, Moritz Binder, MDMPH, Shakila P Khan, MD, Vilmarie Rodriguez, MD, Naseema Gangat, MBBS, Alexandra Wolanskyj, MD, Rajiv K. Pruthi, MBBS, Dong Chen, MD PhD, Rong He, MD, David S Viswanatha, MD, Terra Lasho, PhD, Christy Finke, BS, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD, Mark Litzow, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 3003.

https://doi.org/10.1182/blood-2019-124830

Published: 2019

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group

Blood (2019) 134 (Supplement_1): 2946.

https://doi.org/10.1182/blood-2019-124854

Published: 2019

Journal Articles

Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients

Blood (2019) 134 (Supplement_1): 3005.

https://doi.org/10.1182/blood-2019-124115

Published: 2019

Journal Articles

Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea

Byung-Hyun Lee, MD, Hyemi Moon, Ka-Won Kang, Byung Soo Kim, Yong Park

Blood (2019) 134 (Supplement_1): 2951.

https://doi.org/10.1182/blood-2019-122156

Published: 2019

Journal Articles

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Francesco Passamonti, MD, Lynda Foltz, MD FRCPC, David M Ross, MD PhD, Nicola Vianelli, MD, Alessandro M. Vannucchi, MD, Norio Komatsu, MD PhD, Pierre Zachée, Ranjan Tiwari, MSc, Evren Zor, MD, Shalini Chaturvedi, Geralyn Gilotti, MSc, Francisco Cervantes, MD

Blood (2019) 134 (Supplement_1): 2952.

https://doi.org/10.1182/blood-2019-124739

Published: 2019

Journal Articles

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2948.

https://doi.org/10.1182/blood-2019-124343

Published: 2019

Journal Articles

Copper Deficiency and Cytopenia: A Systematic Review

Prakash Kharel, MD, Karthik Gnanapandithan, MD MS, Ramesh Kumar Pandey, MD, Samir Jha, Alyssa Grimshaw, MSLIS, Smith Giri, MBBS

Blood (2019) 134 (Supplement_1): 5025.

https://doi.org/10.1182/blood-2019-132265

Published: 2019

Journal Articles

Rebound Thrombocytosis after Induction Chemotherapy Is a Strong Biomarker for Favorable Outcome in AML Patients

Thomas Pabst, MD, Bianca R Schnell, Ulrike Bacher, Barbara Jeker, Yara Banz, Urban Novak, Katja - Seipel

Blood (2019) 134 (Supplement_1): 5101.

https://doi.org/10.1182/blood-2019-127984

Published: 2019

Journal Articles

JAK-2-Positive Latent Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis- from the Hematopathology Perspective

Dina Sameh Soliman, MD MB, MMSc, Aliaa Amer, MD, Firyal Ibrahim, MD, Ahmad Al-Sabbagh, MD, Halima El-Omri, MD, Mohamed A Yassin, MBBS, MSc, Susanna Jane Akiki, PhD

Blood (2019) 134 (Supplement_1): 5381.

https://doi.org/10.1182/blood-2019-128421

Published: 2019

Journal Articles

Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption

Alexander A Boucher, MD, Min Dong, PhD, Anu Marahatta, PhD, Adriane Hausfeld, Thad A. Howard, MS, Jaimie D Nathan, MD, Alexander A. Vinks, PharmD, PhD FCP, Patrick T. McGann, MD, Russell E. Ware, MD PhD, Lori Luchtman-Jones, MD

Blood (2019) 134 (Supplement_1): 4893.

https://doi.org/10.1182/blood-2019-127378

Published: 2019

Journal Articles

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Zara Sayar, MD FRCPath, MRCP, Anna Weatherill, Stephen Keddie, Jonathan Sive, MD, Michael P Lunn, Mari Thomas, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 714.

https://doi.org/10.1182/blood-2019-125639

Published: 2019

Journal Articles

Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

Blood (2019) 134 (Supplement_1): 839.

https://doi.org/10.1182/blood-2019-127488

Published: 2019

Journal Articles

Characterization of the Rate, Predictors, and Thrombotic Complications of Thrombocytosis in Iron Deficiency Anemia

Andrew B Song, BA, David J. Kuter, Hanny Al-Samkari, MD

Blood (2019) 134 (Supplement_1): 959.

https://doi.org/10.1182/blood-2019-122359

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The role of AGK in thrombocytopoiesis and possible therapeutic strategies

Eltrombopag for Immune Thrombocytopenia Adult Patients in the Real-Life Practice in France. Interim Results of the Elextra Study

Megakaryocyte Ablation Ameliorates Bone Marrow Fibrosis By Reducing Myofibroblast Differentiation in a Mouse Model of Primary Myelofibrosis

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

High Platelet Counts, Thrombosis, Bleeding Signs, and Acquired Von Willebrand Syndrome at Diagnosis of Pediatric Chronic Myeloid Leukemia

Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group

Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients

Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Copper Deficiency and Cytopenia: A Systematic Review

Rebound Thrombocytosis after Induction Chemotherapy Is a Strong Biomarker for Favorable Outcome in AML Patients

JAK-2-Positive Latent Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis- from the Hematopathology Perspective

Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

Characterization of the Rate, Predictors, and Thrombotic Complications of Thrombocytosis in Iron Deficiency Anemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only